Wells Fargo Maintains Overweight on Metagenomi Therapeutics, Lowers Price Target to $7

Benzinga · 3d ago
Wells Fargo analyst Yanan Zhu maintains Metagenomi Therapeutics (NASDAQ:MGX) with a Overweight and lowers the price target from $9 to $7.